Published in Pharma Law Weekly, November 28th, 2006
Third quarter 2006 was favorably impacted by net prior period amounts of approximately $3,244,000 pre-tax, or $0.04 per diluted share net of income taxes. Excluding the impact of these prior period amounts, third quarter net income would have been $22,592,000 or $0.42 per diluted share.
For the 9 months ended September 30, 2006, net income increased 89.4% to $77,162,000, or $1.46 per diluted share compared with $40,731,000, or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.